PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...
Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...
Venetoclax is under clinical development by AbbVie and currently in Phase II for Refractory Acute Myeloid Leukemia.
A young man has been diagnosed with acute stage 3 leukemia and urgently needs help to survive. He has appealed to the general ...
LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody®First-in-human study enrolling adult patients with CD123-expressing AML or ...
The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...
Acute myeloid leukemia (AML) is an aggressive bone marrow disease. Despite advances in treatment, AML remains a therapeutic challenge due to high rates of ...
Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...
In a significant advancement for cancer research, a team of scientists from Max Planck Institute for Biology Tübingen, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback